SUNRISE, Fla., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today that it is planning to spin out or sell off its interest in several non-core technology platforms in order to intensify its strategic focus on the treatment of patients suffering from heart failure. Bioheart holds the rights to multiple patents and patents pending related to these non-core technologies as well as proprietary know-how and trade secrets. Animal data supporting the proof of concept for some of these technologies is also available from the Company.
